Eliezer Van Allen
Has grant
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Dissecting the impact of noncoding structural variation in melanoma genomes
Open Date: 2021-06-01
Close Date: 2023-05-31
Articles (49)
Year:
2026
Year:
2026
Year:
2026
Categorical variants, or sets of genomic alterations constrained by shared properties, are pervasive across clinical, regulatory, and research domains in the biomedical ecosystem, yet their inconsistent and non-computable representation hinders data interoperability and clinical interpretation. We surveyed genomic knowledgebases spanning regulatory approvals and the biomedical literature and found that categorical variants underpin a substantial proportion of clinical genomics knowledge, but are largely described using incompatible bespoke models. To address this, we developed the GA4GH Categorical Variation Representation Specification (Cat-VRS), a constraint-based framework that provides a unified computable representation for both precise and intentionally broad categories across molecular and systemic variant domains. Cat-VRS enables harmonization of genomic knowledgebases, computable category-based search, and automated matching between assayed variants and categorical entities in clinical and research contexts. By providing a principled, extensible model for categorical variation, Cat-VRS enables computable reasoning over genomic variant categories and establishes a foundation for the standardized representation and exchange of genomic knowledge.
Year:
2026
New approaches that generate long-lasting therapeutic responses in patients with therapy-resistant metastatic cancer are urgently needed. To address this challenge, we developed Spot Neoantigens in Metastases (SpotNeoMet), a novel data-driven pipeline that systematically identifies recurrently presented neopeptides in treatment-resistant patients. We identified seven therapy resistance mutations predicted to produce neopeptides presented by common HLAs. Using HLA immunopeptidomics, we discovered three novel neopeptides derived from androgen receptor (AR) H875Y, a common metastatic castration-resistant prostate cancer (mCRPC) mutation. We validated these neoantigens as highly immunogenic and then isolated and characterized cognate T-cell receptors (TCR) from healthy donor peripheral blood mononuclear cells. We demonstrated that AR H875Y–specific TCRs are highly specific and kill prostate cancer cells presenting AR neopeptides in vitro and in vivo . Our new pipeline identifies novel immunotherapy targets and potential treatment options for patients with mCRPC. Moreover, SpotNeoMet offers a systematic route to identify “HLA–peptide” pairs and their cognate TCRs across treatment-resistant cancers. Significance: As the emergence of resistance to targeted treatments in patients with metastatic cancer, there is an urgent need for innovative therapeutic approaches for this population. Our study provides a new analytic framework to identify neoantigens from treatment-resistant mutations and a proof-of-concept T cell–based immunotherapy treatment for mCRPC.
Year:
2026
Year:
2025
Year:
2025
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are clinically heterogeneous malignancies whose biology and microenvironmental organization remain poorly understood. Here, we integrated single-nucleus multiomic (snRNA-seq and snATAC-seq) and spatial transcriptomic profiling across 38 well-differentiated pancreatic (pNET) and small-intestinal (siNET) tumors to define conserved malignant programs, their regulatory circuits, and spatial niches. We observed two conserved malignant cell programs spanning a continuous transcriptional spectrum: a neuronal-like program (si-cNMF1/p-cNMF1), and a secretory neuroendocrine program (si-cNMF2/p-cNMF2). Matched chromatin accessibility profiles uncovered distinct, tissue-specific regulatory networks, including MAX::MYC and MITF transcription factor binding motifs in siNETs versus ISL1 and TFAP4 in pNETs, indicating organ-specific epigenetic control. Spatial transcriptomic analyses revealed that si/p-cNMF1-high regions localized to high cell density, immune-rich tumor areas, whereas si/p-cNMF2-high regions occupied stromal and vascularized niches and co-occured with fibroblast and endothelial compartments enriched for TGFB1-ITGB1 , VEGFA-FLT1 , and LAMA2-ITGA1 signaling. Across both tumor types, the cNMF2 program was enriched in metastatic lesions and was enrichedfor pro-fibrotic and pro-angiogenic gene signatures. Thus, GEP-NETs are organized along a conserved neuronal-to-secretory axis defined by distinct epigenetic programs and spatially coupled to specific microenvironmental niches. This framework unifies NET heterogeneity across organ sites and identifies pathway-specific, microenvironment-linked vulnerabilities for therapeutic targeting.
Year:
2025
Introduction Precision oncology has informed cancer care by enabling the discovery and application of diagnostic, prognostic, and/or predictive molecular biomarkers. However, many patients lack actionable biomarkers or fail to respond to biomarker-directed therapies. Patient similarity approaches can leverage comprehensive tumor profiling and prior clinical experiences from large cohorts for decision support, facilitating broader realization of precision oncology insights. Methods We developed a deep learning-based modeling framework using real-world clinicogenomic data from a tertiary cancer center to (i) measure patient similarity based on embedded tumor genomic profiles and (ii) evaluate the association of derived patient subgroups and neighborhoods with shared therapeutic outcomes in breast cancer-specific and histology-agnostic pan-cancer settings. Results The model recovered clinically meaningful patient clusters reflecting both expected and previously unknown therapeutic associations, as well as patient-specific neighborhoods that could inform therapeutic trajectories more often than expected by chance in multiple clinical contexts. Moreover, model utility extended to patients without actionable genomic biomarkers and those with cancer of unknown primary (CUP) diagnoses, where neighborhoods aligned with independently predicted primary cancer type. These neighborhoods could also be examined over time in a continuously learning scenario. Conclusion This similarity-based modeling framework distilled complex molecular and clinical data into concise, context-specific insights that augment clinician judgment, providing a foundation for a real-time learning, patient-centered decision support model in precision oncology.
Year:
2025
Persistent stable lesions represent a common but ambiguous outcome in melanoma patients receiving immune checkpoint inhibitors (ICIs). However, these lesions are infrequently removed and poorly characterized. Here, we perform in-depth multi-omics spatial profiling on persistent stable lesions from six ICI-treated patients. In one, the proportion of viable and proliferating tumor cells was similar to that of site-matched tumors from patients progressing during ICI. Extensive infiltration with cytotoxic T cells and a high level of programmed cell death were also observed. Some quiescent cancer cells were present, but this was not the dominant tumor state. A second stable lesion, while pathologically negative, also contained proliferative tumor nests with proximate immune cells. These findings provide evidence in patients for extended tumor mass dormancy in which cell death balances ongoing proliferation and further demonstrate that persistent stable lesions can be reservoirs of viable tumor cells with implications for clinical monitoring and management. SIGNIFICANCE This study demonstrates that, following immunotherapy, persistent stable melanomas can arise through tumor mass dormancy rather than quiescence. Mass dormancy is characterized by active tumor cell proliferation and compensatory programmed cell death. Thus, viable tumor cells in some stable lesions have the potential to reactivate disease should ongoing immunosurveillance fail.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (71)
Lucia Kwak
Johns Hopkins University
Filippo Birocchi
Harvard University
Madeleine Torcasso
Assistant Professor
University of Chicago
Roni Oren
Head of Patient Derived Xenograft (PDX) Service and Human Tissue Samples Bank
Weizmann Institute of Science
Ulka Vaishampayan
Professor
University of Michigan
David Braun
Assistant Professor, Principal Investigator
Yale University Yale Cancer Center
Andréanne Gagné
Assistant Professor
Université Laval
Olga Troyanskaya
Professor
Princeton University
Francisco Martínez-Jiménez
Group Leader
Vall d'Hebron Institute of Oncology
Alexander Jordan
Assistant Professor
Yale University
Stephanie Dougan
Associate Professor
Dana-Farber Cancer Institute
Sandro Santagata
Brigham and Women's Hospital
Bose Kochupurakkal
Senior Scientist
Dana-Farber Cancer Institute
Akash Patnaik
Deputy Chief for Translational Research
University of Chicago
David A. Quigley
Assistant Professor
University of California, San Francisco
Ali Amiryousefi
University of Helsinki
Ben Stanger
University of Pennsylvania
Biren Saraiya
Assistant Professor of Medicine
Rutgers Cancer Institute of New Jersey
Fabian Theis
Director of the Institute of Computational Biology and Professor
Technical University of Munich
Rahul Parikh
Associate Professor of Medicine
University of Kansas Medical Center
Roxana Daneshjou
Stanford University
Alexander W. Wyatt
Assistant Professor
The University of British Columbia
Christopher Reilly
Assistant Professor
Dana-Farber Cancer Institute
Christine Lian
Dermatopathologist/Associate Professor
Brigham and Women's Hospital
Peter Winter
Principal Investigator
Broad Institute
Ryan Collins
Principal Investigator
Dana-Farber Cancer Institute
Srinivas Viswanathan
Dana-Farber Cancer Institute
Toni Choueiri
Director, Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Shifra Ben-Dor
Senior Staff Scientist
Weizmann Institute of Science
David Kim
Assistant Professor
Stanford University
Wenxin Xu
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Niroshana Anandasabapathy
Associate Professor of Dermatology
Weill Cornell Medical College
Cheng-Zhong Zhang
Assistant Professor
Dana-Farber Cancer Institute
Elizabeth Buchbinder
Harvard University
Abel Gonzalez-Perez
Co-PI
IRB Barcelona
Valentina Boeva
Tenure Track Assistant Professor
ETH Zürich
Paola A. Guerrero
Research Group Leader
The University of Texas MD Anderson Cancer Center
Christopher J. Sweeney
University of Adelaide
Joaquin Mateo
Group Leader
Vall d´Hebron Institute of Oncology
Giuseppe Nicolò Fanelli
University of Pisa
Franklin W. Huang
-
Alex Wagner
Associate Professor
The Ohio State University College of Medicine
Srivatsan Raghavan
Assistant Professor
Dana-Farber Cancer Institute
Eddy Saad
Dana-Farber Cancer Institute
Lawrence Fong
Fred Hutch Cancer Center
Filipe Carvalho
Brigham and Women's Hospital
Brandon Chen
University of California, San Francisco
David Yang
Dana-Farber Cancer Institute
David S. Hong
The University of Texas MD Anderson Cancer Center
Neal Lindeman
Vice Chair, Molecular Pathology and Laboratory Medicine
Weill Cornell Medicine
Peter Sorger
Otto Krayer Professor of Systems Pharmacology
Harvard Medical School
Alan D'Andrea
Director, Center for DNA Damage and Repair
Dana-Farber Cancer Institute
Leandra Barnes
Stanford University
David Liu
Assistant Professor
Dana-Farber Cancer Institute
Aedin Culhane
Professor of Cancer Genomics
University of Limerick
Yishai Levin
Lab head
Weizmann Institute of Science
Atish Choudhury
Dana-Farber Cancer Institute
Adam Olson
Assistant Professor
UPMC Hillman Cancer Center
Simona Cristea
Dana-Farber Cancer Institute
Anirban Maitra
Laura and Isaac Perlmutter Professor of Pathology
NYU Langone Health
Michael P. Kim
Associate Professor
The University of Texas MD Anderson Cancer Center
S. Percy Ivy
Associate Chief
National Cancer Institute
Nuria Lopez-Bigas
ICREA Research Professor-Group Leader
Universitat Pompeu Fabra
Bradley McGregor
Dana-Farber Cancer Institute
Sirisha V Mukkavalli
Senior Scientist/Lab Manager
Dana-Farber Cancer Institute
Rana R. McKay
University of California, San Diego
Shubham Pant
Professor
The University of Texas MD Anderson Cancer Center
David McDermott
Beth Israel Deaconess Medical Center
Alex K. Shalek
J. W. Kieckhefer Professor
Massachusetts Institute of Technology
Mamta Parikh
Associate Professor
University of California Davis Comprehensive Cancer Center
Jennifer Roth
Broad Institute
Make your next move.
Prepare your application
Review drafts before you send them.